314 results on '"Bellentani S"'
Search Results
2. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
- Author
-
Mascolo, M.C., Cursaro, C., Scuteri, A., Ranieri, J., Monti, M., Bellentani, S., Gasbarrini, A., Pompili, M., Puoti, C., Bellis, L., Regazzetti, A., Maffezzini, E., Pietrangelo, A., Abbati, G., Raimondo, G., Scribano, L., Martines, D., Baroni, G. Svegliati, Faraci, G., Schianchi, S., Fornaciari, G., Fabris, P., Madonia, S., Civitavecchia, G., Pirisi, M., Smirne, C., Borghi, A., Sardini, C., Andreoletti, M., Morisco, F., Caporaso, N., Fargion, S., Fatta, E., Masutti, F., Bonaventura, M.E., Autolitano, A., Russello, M., Bellia, A., Toniutto, P., Bitetto, D., Mecenate, F., Pasulo, L., Lucà, M.G., Picardi, A., Vespasiani, U., Grattagliano, I., Palasciano, G., Romagno, D., Crespi, C., Gianstefani, A., Gobbo, G., Monti, V., Giannelli, G., Napoli, N., Nosotti, Raspanti, A., Cuccorese, Colombo, A.E., Floridia, Plattella, M.S., Cassano, P., Gentile, I., Blanc, P.L., Messina, V., Bonfante, S., Bellissima, P., Toti, M., Vecchiet, J., Falasca, K., Portelli, V., De Stefano, G., Pietromatera, G., Viganò, P., Re, T., Andreoni, M., Raineri, G., Massari, M., Grossi, P.A., Caputo, S., Cassola, G., Feasi, M., Foti, G., Kunkar, A., Corti, G., Baragli, F., Caterini, L., Migliorini, D., Chiodera, A., Calleri, G., Spezia, C., Baiguera, C., Puoti, M., Brancaccio, G., Gaeta, G.B., Vento, S., Di Biagio, A., Nicolini, L., Liberti, A., Iannece, M.D., Contini, C., Tacconi, D., Caremani, M., Almi, P., Chimenti, M., Cosco, Messeri, D., Esperti, F.C., Paffetti, A., Mastropietro, C., Moretti, A., Spagnolo, A.L., Lomonaco, L., Calì, A., Mandelli, G., Spinzi, G.C., Framarin, L., Berrutti, M., Boccia, S., Simone, L., Pazzi, P., Fornari, F., Comparato, G., Casetti, T., Foschi, F.G., Bertin, T., Salvagnini, M., Samori, A., Ferretti, E., Casiraghi, M.A., Marin, R., Ciancio, A., Campo, N., Testa, R., Rocco, A., Federico, A., Loguercio, C., Rizzo, S., Giannini, E.G., Corbo, M., Riegler, G., Esposito, P., Ricci, G.L., Rosina, Floriano, Tosti, Maria Elena, Borghesio, Elisabetta, Masocco, Maria, Mele, Alfonso, Coppola, Carmine, Milella, Michele, Borgia, Guglielmo, Andreone, Pietro, Koch, Maurizio, Zignego, Anna Linda, Romano, Mario, Carrara, Maurizio, Almasio, Piero Luigi, Azzola, Emilio, Nardone, Gerardo, Benedetti, Antonio, Carosi, Giampiero, Mazzotta, Francesco, Sagnelli, Evangelista, and Rizzetto, Mario
- Published
- 2014
- Full Text
- View/download PDF
3. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?
- Author
-
Foschi F. G., Domenicali M., Giacomoni P., Dall'Aglio A. C., Conti F., Borghi A., Bevilacqua V., Napoli L., Mirici F., Cucchetti A., Ercolani G., Gardini A. C., Bellentani S., Gastaldelli A., Giuffre M., Tiribelli C., Bedogni G., BEDOGNI, GIORGIO, Foschi F.G., Domenicali M., Giacomoni P., Dall'Aglio A.C., Conti F., Borghi A., Bevilacqua V., Napoli L., Mirici F., Cucchetti A., Ercolani G., Gardini A.C., Bellentani S., Gastaldelli A., Giuffre M., Tiribelli C., and Bedogni G.
- Subjects
Liver Cirrhosis ,Male ,Percentile ,Cross-sectional study ,Epidemiology ,Specialties of internal medicine ,Chronic liver disease ,Gastroenterology ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,Medicine ,Metabolic Syndrome ,education.field_of_study ,Elasticity imaging technique ,Alanine Transaminase ,gamma-Glutamyltransferase ,General Medicine ,Middle Aged ,RC581-951 ,030220 oncology & carcinogenesis ,Elasticity Imaging Techniques ,Biomarker (medicine) ,Female ,030211 gastroenterology & hepatology ,Fatty Liver, Alcoholic ,Adult ,medicine.medical_specialty ,Population ,Liver fibrosis ,03 medical and health sciences ,Internal medicine ,BAAT ,Humans ,Clinical significance ,Aspartate Aminotransferases ,Obesity ,education ,Hepatology ,Platelet Count ,business.industry ,Cholesterol, HDL ,Cholesterol, LDL ,Biomarker ,Overweight ,medicine.disease ,business ,Transient elastography ,Biomarkers - Abstract
Introduction and objectives Surrogate biomarkers of liver fibrosis developed in tertiary care are increasingly used in general populations. We evaluated the association between liver stiffness (LS) and five continuous (AST/ALT, APRI, Forns Index, FIB-4, GGT) and two discrete biomarkers (BARD, BAAT) in a general population. Patients and methods 636 (29%) of the 2159 citizens of the Bagnacavallo Study had LS measured by transient elastography. Using linear regression with univariate multiple imputation, we evaluated the association of LS with the above biomarkers in the total sample of 2159 citizens. Results The mean change of LS between the 5th and 95th internal percentile of any continuous biomarker was ≤1 kPa. The mean change of LS between scores 0 and 3 of BARD and scores 0 and ≥3 of BAAT was >1 kPa but of doubtful clinical relevance. Conclusion We found a modest association between LS and seven biomarkers of liver fibrosis in a general population.
- Published
- 2020
4. OC-14Fatty liver Index (FLI) 15 years later: a SANRA (Scale for the quality Assessment of Narrative Review Articles) reappraisal.
- Author
-
Lonardo, A., primary, Ballestri, S., additional, Bedogni, G., additional, Bellentani, S., additional, and Tiribelli, C., additional
- Published
- 2021
- Full Text
- View/download PDF
5. Predictors of non-alcoholic fatty liver disease in obese children
- Author
-
Sartorio, A, Del Col, A, Agosti, F, Mazzilli, G, Bellentani, S, Tiribelli, C, and Bedogni, G
- Published
- 2007
- Full Text
- View/download PDF
6. Could inflammatory indices and metabolic syndrome predict the risk of cancer development? Analysis from the bagnacavallo population study
- Author
-
Rimini, M., Casadei-Gardini, A., Ravaioli, A., Rovesti, G., Conti, F., Borghi, A., Dall'Aglio, A. C., Bedogni, G., Domenicali, M., Giacomoni, P., Tiribelli, C., Bucchi, L., Falcini, F., Foschi, F. G., Gastaldelli, A., Ercolani, G., Cucchetti, A., Dazzani, F., Bevilacqua, V., Napoli, L., Mirici, F., Bellentani, S., Lanzi, A., Saini, G., Bernardi, M., Andreone, P., and Stefanini, G. F.
- Subjects
Breast cancer ,Cancer incidence ,Colon cancer ,Inflammatory indices ,Lung cancer ,Metabolic Syndrome ,NLR ,PLR ,SII - Published
- 2020
7. External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study
- Author
-
Foschi, F. G., Conti, F., Domenicali, M., Giacomoni, P., Borghi, A., Bevilacqua, V., Napoli, L., Berardinelli, D., Altini, M., Cucchetti, A., Ercolani, G., Casadei-Gardini, A., Bellentani, S., Gastaldelli, A., Tiribelli, C., Bedogni, G., Andreone, P., Dall'Aglio, A. C., Bernardi, M., Bucchi, L., Dazzani, F., Falcini, F., Lanzi, A., Ravaioli, A., Rimini, M., Rovesti, G., Saini, G., Stefanini, G. F., Foschi, Francesco Giuseppe, Conti, Fabio, Domenicali, Marco, Giacomoni, Pierluigi, Borghi, Alberto, Bevilacqua, Vittoria, Napoli, Lucia, Berardinelli, Dante, Altini, Mattia, Cucchetti, Alessandro, Ercolani, Giorgio, Casadei-Gardini, Andrea, Bellentani, Stefano, Gastaldelli, Amalia, Tiribelli, Claudio, Bedogni, Giorgio, and Group, Bagnacavallo Study
- Subjects
medicine.medical_specialty ,Validation study ,Calibration (statistics) ,Population ,lcsh:Medicine ,Gastroenterology ,Article ,diagnostic techniques and procedures ,03 medical and health sciences ,0302 clinical medicine ,Fatty liver ,Internal medicine ,Diagnostic techniques and procedures ,medicine ,cross-sectional study ,030212 general & internal medicine ,education ,Cross-sectional study ,fatty liver ,education.field_of_study ,business.industry ,lcsh:R ,fungi ,External validation ,non-alcoholic fatty liver disease ,General Medicine ,medicine.disease ,validation study ,diagnostic techniques and procedure ,030211 gastroenterology & hepatology ,Steatosis ,business ,Non-alcoholic fatty liver disease ,Lipid Accumulation Product - Abstract
We externally validated the fatty liver index (FLI), the lipid accumulation product (LAP), the hepatic steatosis index (HSI), and the Zhejiang University index (ZJU) for the diagnosis of fatty liver (FL) and non-alcoholic fatty liver disease (NAFLD) in the general population. The validation was performed on 2159 citizens of the town of Bagnacavallo (Ravenna, Italy). Calibration was evaluated by calculating the calibration slope and intercept and by inspecting calibration plots, discrimination was evaluated using the c-statistic. The average calibration slope was 1 and the average intercept was 0 for all combinations of outcomes and indices. For the diagnosis of FL, the c-statistic was 0.85 for FLI, 0.83 for ZJU, 0.82 for HSI, and 0.80 for LAP, for the diagnosis of NAFLD, the c-statistic was 0.77 for FLI, 0.76 for ZJU, 0.75 for HSI, and 0.74 for LAP. All indices were strongly correlated with each other. In conclusion, FLI, LAP, HSI, and ZJU perform similarly well to diagnose FL and NAFLD in the Bagnacavallo population, even if FLI has a small advantage as discrimination is concerned.
- Published
- 2021
8. Cow’s Milk Consumption and Health: A Health Professional’s Guide
- Author
-
Marangoni, F., Pellegrino, L., Verduci, E., Ghiselli, A., Bernabei, Roberto, Calvani, Riccardo, Cetin, I., Giampietro, M., Perticone, F., Piretta, L., Giacco, R., La Vecchia, C., Brandi, M. L., Ballardini, D., Banderali, G., Bellentani, S., Canzone, G., Cricelli, C., Faggiano, P., Ferrara, N., Flachi, E., Gonnelli, S., Macca, C., Magni, P., Marelli, G., Marrocco, W., Miniello, V. L., Origo, C., Pietrantonio, Filomena, Silvestri, P., Stella, R., Strazzullo, P., Troiano, E., Poli, A., Bernabei R. (ORCID:0000-0002-9197-004X), Calvani R. (ORCID:0000-0001-5472-2365), Pietrantonio F., Marangoni, F., Pellegrino, L., Verduci, E., Ghiselli, A., Bernabei, Roberto, Calvani, Riccardo, Cetin, I., Giampietro, M., Perticone, F., Piretta, L., Giacco, R., La Vecchia, C., Brandi, M. L., Ballardini, D., Banderali, G., Bellentani, S., Canzone, G., Cricelli, C., Faggiano, P., Ferrara, N., Flachi, E., Gonnelli, S., Macca, C., Magni, P., Marelli, G., Marrocco, W., Miniello, V. L., Origo, C., Pietrantonio, Filomena, Silvestri, P., Stella, R., Strazzullo, P., Troiano, E., Poli, A., Bernabei R. (ORCID:0000-0002-9197-004X), Calvani R. (ORCID:0000-0001-5472-2365), and Pietrantonio F.
- Abstract
The most recent scientific evidence supports the consumption of cow’s milk and dairy products as part of a balanced diet. However, these days, the public and practicing physicans are exposed to a stream of inconsistent (and often misleading) information regarding the relationship between cow’s milk intake and health in the lay press and in the media. The purpose of this article, in this context, is to facilitate doctor–patient communication on this topic, providing physicians with a series of structured answers to frequently asked patient questions. The answers range from milk and milk-derived products’ nutritional function across the life span, to their relationship with diseases such as osteoporosis and cancer, to lactose intolerance and milk allergy, and have been prepared by a panel of experts from the Italian medical and nutritional scientific community. When consumed according to appropriate national guidelines, milk and its derivatives contribute essential micro- and macronutrients to the diet, especially in infancy and childhood where bone mass growth is in a critical phase. Furthermore, preliminary evidence suggests potentially protective effects of milk against overweight, obesity, diabetes, and cardiovascular disease, while no clear data suggest a significant association between milk intake and cancer. Overall, current scientific literature suggests that an appropriate consumption of milk and its derivatives, according to available nutritional guidelines, may be beneficial across all age groups, with the exception of specific medical conditions such as lactose intolerance or milk protein allergy. Key teaching points: Milk and its derivatives contribute essential micro and macronutrients to the diet, when consumed according to appropriate national guidelines, especially in infancy and childhood where bone mass growth is in a critical phase. Preliminary evidence suggests potentially protective effects of milk against overweight, obesity, diabetes and cardio
- Published
- 2019
9. The North-to-South Gradient of Hepatitis C Virus Infection
- Author
-
Tiribelli, C, Bellentani, S, and Campello, C
- Published
- 2003
10. Body mass index is a good predictor of an elevated alanine transaminase level in the general population: hints from the Dionysos study
- Author
-
Bedogni, G, Miglioli, L, Battistini, N, Masutti, F, Tiribelli, C, and Bellentani, S
- Published
- 2003
- Full Text
- View/download PDF
11. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort
- Author
-
Lenzi, M, Bellentani, S, Saccoccio, G, Muratori, P, Masutti, F, Muratori, L, Cassani, F, Bianchi, F B, and Tiribelli, C
- Published
- 1999
12. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study
- Author
-
Bellentani, S, Pozzato, G, Saccoccio, G, Crovatto, M, Croce, L S, Mazzoran, L, Masutti, F, Cristianini, G, and Tiribelli, C
- Published
- 1999
13. DNA OXIDATIVE DAMAGE SIGNIFICANTLY CORRELATE WITH THE DEGREE OF LIVER DAMAGE IN A GENERAL POPULATION OF ANTI-HCV POSITIVE PATIENTS
- Author
-
Gardin, R., Saccoccio, G., Masutti, F., Bellentani, S., Farinati, F., and Tiribelli, C.
- Published
- 1999
14. Drinking habits as cofactors of risk for alcohol induced liver damage
- Author
-
Bellentani, S, Saccoccio, G, Costa, G, Tiribelli, C, Manenti, F, Sodde, M, Croce', L Saveria, Sasso, F, Pozzato, G, Cristianini, G, and Brandi, G
- Published
- 1997
15. C01/020 HCV GENOTYPE DISTRIBUTION IN THE GENERAL POPULATION OF NORTHERN ITALY
- Author
-
Bellentani, S., Pozzato, G., Mazzoran, L., Crocè, L. S., Santini, G. F., Crovatto, M., Barbisin, M., Saccoccio, G., and Tiribelli, C.
- Published
- 1996
16. GS6/036 EFFECT OF ETHANOL ON CYTOKINE EXPRESSION IN HepG2 CELLS AND MODULATION BY BILE ACIDS
- Author
-
Neuman, M. G., Shear, N. H., Bellentani, S., and Tiribelli, C.
- Published
- 1996
17. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
- Author
-
Munteanu, M., Tiniakos, D., Anstee, Q., Charlotte, F., Marchesini, G., Bugianesi, E., Trauner, M., Romero Gomez, M., Oliveira, C., Day, C., Dufour, J.‐F., Bellentani, S., Ngo, Y., Traussnig, S., Perazzo, H., Deckmyn, O., Bedossa, P., Ratziu, V., Poynard, T., Ratziu, Vlad, Poynard, Thierry, Castille, Jean‐Marie, Ngo, Yen, Langon, Tania, Day, Chris, Tiniakos, Dina, Lawlor, Debbie, Marchesini, Giulio, Marra, Fabio, Bugianesi, Elisabetta, Bellentani, Stefano, Dufour, Jean‐François, Romero Gomez, Manuel, Sørensen, Thorkild, Tribelli, Claudio, De Minicis, Samuele, Trauner, Michael, Oliveira, Claudia, Bedossa, Pierre, Burt, Alastair D., Gouw, Annette S.H., Lackner, Carolin, Schirmacher, Peter, Terracciano, Luigi, Brain, J., Bury, Yvonne, Cabibi, Daniela, Charlotte, Frederic, David, Ezio, Losi, Luisa, Montani, Matteo, Pareja, Marıa Jesus, Wendum, Dominique, Wrba, Fritz, Ziol, Marianne, Thabut, Dominique, Moussalli, Joseph, Lebray, Pascal, Rudler, Marika, Bismuth, Françoise Imbert, Rosmorduc, Olivier, Calmus, Yvon, Hartemann, Agnes, Jacqueminet, Sophie, Bruckert, Eric, Giral, Philippe, Naveau, Sylvie, Perlemuter, Gabriel, Varsat, Brigitte, Mercadier, Anne, Biopredictive, National and Kapodistrian University of Athens (NKUA), Newcastle University [Newcastle], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Università degli studi di Torino (UNITO), Medizinische Universität Wien = Medical University of Vienna, Universidad de Sevilla, University of São Paulo School of Medicine, Universität Bern [Bern], Università degli Studi di Modena e Reggio Emilia (UNIMORE), Université Pierre et Marie Curie - Paris 6 (UPMC), Hôpital Beaujon, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), National and Kapodistrian University of Athens = University of Athens (NKUA | UoA), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Università di Bologna [Bologna] (UNIBO), Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Munteanu, M., Tiniakos, D., Anstee, Q., Charlotte, F., MARCHESINI REGGIANI, Giulio, Bugianesi, E., Trauner, M., Romero Gomez, M., Oliveira, C., Day, C., Dufour, J. F., Bellentani, S., Ngo, Y., Traussnig, S., Perazzo, H., Deckmyn, O., Bedossa, P., Ratziu, V., Poynard, T., Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Università degli studi di Torino = University of Turin (UNITO), Universidad de Sevilla / University of Sevilla, Universität Bern [Bern] (UNIBE), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Biopsy ,610 Medicine & health ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Fibrosis ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Prospective Studies ,Stage (cooking) ,Prospective cohort study ,Grading (tumors) ,Inflammation ,Hematologic Tests ,Hepatology ,medicine.diagnostic_test ,business.industry ,FibroTest ,Fatty liver ,Middle Aged ,medicine.disease ,3. Good health ,Non‐invasive Tests of Nafld ,Fatty Liver ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Original Article ,Female ,Steatosis ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
the FLIP Consortium and the FibroFrance Group; International audience; BackgroundBlood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis.AimsTo improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading.MethodsWe pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary-ROC (NonBinAUROC) as the main endpoint to prevent spectrum effect and multiple testing.ResultsA total of 600 patients with reliable tests and biopsies were included. The mean NonBinAUROCs (95% CI) of tests were all significant (P < 0.0001): 0.878 (0.864–0.892) for FibroTest and fibrosis stages, 0.846 (0.830–0.862) for ActiTest and activity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest had a higher NonBinAUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB4 (0.845; 0.829–0.861; P = 0.007) but not significantly different than the NAFLD score (0.866; 0.850–0.882; P = 0.26). FibroTest had a significant difference in median values between adjacent stage F2 and stage F1 contrarily to BARD, FIB4 and NAFLD scores (Bonferroni test P < 0.05).ConclusionsIn patients with NAFLD, SteatoTest, ActiTest and FibroTest are non-invasive tests that offer an alternative to biopsy, and they correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD: steatosis, inflammatory activity and fibrosis.
- Published
- 2016
18. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
- Author
-
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., Miele, Luca, Morisco, F., Petta, S., Piscaglia, F., Svegliati-Baroni, G., Valenti, L., Bellentani, S., Miele L. (ORCID:0000-0003-3464-0068), Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., Miele, Luca, Morisco, F., Petta, S., Piscaglia, F., Svegliati-Baroni, G., Valenti, L., Bellentani, S., and Miele L. (ORCID:0000-0003-3464-0068)
- Abstract
This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multi-factorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed in-depth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.
- Published
- 2017
19. Mechanisms of Transport of Tauroconjugated Bile Acids in the Hepatocyte: Functional Significance
- Author
-
Bellentani, S., Manenti, F., Hardison, W. G. M., Okolicsányi, Lajos, editor, Csomós, Géza, editor, and Crepaldi, Gaetano, editor
- Published
- 1987
- Full Text
- View/download PDF
20. Interaction of alcohol intake and cofactors on the risk of cirrhosis
- Author
-
Stroffolini, T, Cotticelli, G, Medda, E, Niosi, M, Del Vecchio-Blanco, C, Addolorato, G, Petrelli, E, Salerno, Mt, Picardi, A, Bernardi, M, Almasio, P, Bellentani, S, Surace, La, Loguercio, C, AISF-SIA National Group, Vonghia, L, Volpe, M, Lomazzo, D, D’Avola, D, Caputo, F, Cottone, C, Scaglioni, F, Pontoriero, L, Stroffolini, T, Cotticelli, G, Medda, E, Niosi, M, Del Vecchio-Blanco, C, Addolorato, G, Petrelli, E, Salerno, MT, Picardi, A, Bernardi, M, Almasio, PL, Bellentani, S, Surace, LA, Loguercio, C, Del Vecchio Blanco, C, Salerno, Mt, Almasio, P, Surace, La, Loguercio, Carmelina, Stroffolini T, Cotticelli G, Medda E, Niosi M, Del Vecchio-Blanco C, Addolorato G, Petrelli E, Salerno MT, Picardi A, Bernardi M, Almasio P, Bellentani S, Surace LA, and Loguercio C.
- Subjects
Adult ,Liver Cirrhosis ,Male ,Hepatitis B virus ,Alcohol Drinking ,alcohol, cirrhosis coffee ,Hepacivirus ,Coffee ,Risk Assessment ,cirrhosis coffee ,Body Mass Index ,NO ,Risk Factors ,Odds Ratio ,Humans ,CIRRHOSIS ,Aged ,Hepatitis B Surface Antigens ,alcohol ,Hepatitis C Antibodies ,Middle Aged ,Hepatitis B ,Hepatitis C ,Italy ,Case-Control Studies ,Disease Progression ,RNA, Viral ,Female - Abstract
OBJECTIVE: Evaluation of the interaction between alcohol intake and cofactors [hepatitis B virus (HBV), hepatitis C virus (HCV), body mass index] and coffee consumption on the risk of cirrhosis. DESIGN: Seven hundred and forty-nine consecutive patients with chronic liver disease referring to units for liver or alcohol diseases in Italy during a 6-months period. Teetotalers were excluded. The odds ratios (OR) for cirrhosis were evaluated using chronic hepatitis cases as the control group. RESULTS: An alcohol intake of more than 3 units/day resulted associated with the likelihood of cirrhosis both in males (OR 4.3; 95% CI=2.5-7.3) and in females (OR 5.7; 95% CI=2.3-14.5). A multiplicative interaction on the risk of cirrhosis between risky alcohol intake and HBsAg or HCV-Ab/HCV-RNA positivity was observed. A reduction of cirrhosis risk was observed in subjects consuming more than 3 alcohol units/day with increasing coffee intake. The OR for the association with cirrhosis decreased from 2.3 (95% CI=1.2-4.4) in subjects drinking 0-2 cups of coffee/day to 1.4 (95% CI=0.6-3.6) in those drinking more than 2 cups/day. CONCLUSIONS: In subjects with an alcohol intake >3 units/day the coexistence of HBV or HCV multiplies the risk of cirrhosis. Coffee represents a modulator of alcoholic cirrhosis risk.
- Published
- 2010
21. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
- Author
-
Munteanu, M. Tiniakos, D. Anstee, Q. Charlotte, F. Marchesini, G. Bugianesi, E. Trauner, M. Romero Gomez, M. Oliveira, C. Day, C. Dufour, J.-F. Bellentani, S. Ngo, Y. Traussnig, S. Perazzo, H. Deckmyn, O. Bedossa, P. Ratziu, V. Poynard, T. Castille, J.-M. Langon, T. Lawlor, D. Marra, F. Sørensen, T. Tribelli, C. De Minicis, S. Burt, A.D. Gouw, A.S.H. Lackner, C. Schirmacher, P. Terracciano, L. Brain, J. Bury, Y. Cabibi, D. David, E. Losi, L. Montani, M. Pareja, M.J. Wendum, D. Wrba, F. Ziol, M. Thabut, D. Moussalli, J. Lebray, P. Rudler, M. Bismuth, F.I. Rosmorduc, O. Calmus, Y. Hartemann, A. Jacqueminet, S. Bruckert, E. Giral, P. Naveau, S. Perlemuter, G. Varsat, B. Mercadier, A. the FLIP Consortium the FibroFrance Group
- Abstract
Background: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. Aims: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. Methods: We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary-ROC (NonBinAUROC) as the main endpoint to prevent spectrum effect and multiple testing. Results: A total of 600 patients with reliable tests and biopsies were included. The mean NonBinAUROCs (95% CI) of tests were all significant (P < 0.0001): 0.878 (0.864–0.892) for FibroTest and fibrosis stages, 0.846 (0.830–0.862) for ActiTest and activity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest had a higher NonBinAUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB4 (0.845; 0.829–0.861; P = 0.007) but not significantly different than the NAFLD score (0.866; 0.850–0.882; P = 0.26). FibroTest had a significant difference in median values between adjacent stage F2 and stage F1 contrarily to BARD, FIB4 and NAFLD scores (Bonferroni test P < 0.05). Conclusions: In patients with NAFLD, SteatoTest, ActiTest and FibroTest are non-invasive tests that offer an alternative to biopsy, and they correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD: steatosis, inflammatory activity and fibrosis. © 2016 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd
- Published
- 2016
22. Missed treatment in an Italian HBV infected patients cohort: HBV RER
- Author
-
Cuomo, Gianluca, primary, Borghi, Vanni, additional, Andreone, Pietro, additional, Massari, Marco, additional, Villa, Erica, additional, Pietrangelo, Antonello, additional, Verucchi, Gabriella, additional, Ferrari, Carlo, additional, Ferrari, C., additional, Giuberti, T., additional, Villa, E., additional, Andreone, P., additional, Pietrangelo, A., additional, Abbati, G., additional, Magnani, G., additional, Massari, M., additional, Verucchi, G., additional, Cancellieri, C., additional, Ricca Rosellini, S., additional, Levantesi, F., additional, Mazzella, G., additional, Sacchini, D., additional, Fornaciari, G., additional, Mussini, C., additional, Borghi, V., additional, Foschi, F., additional, Libanore, M., additional, Carradori, S.D., additional, Contini, C., additional, Ballardini, G., additional, Macchia, S., additional, Boccia, S., additional, Vandelli, C., additional, Bassi, P., additional, Zanotti, M., additional, Loria, P., additional, Sbolli, G., additional, Fornari, F., additional, di Maira, P.V., additional, Bellentani, S., additional, Arlotti, M., additional, Grosso, C., additional, Bolondi, G., additional, Pazzi, P., additional, Mazzocchi, A., additional, Govoni, A., additional, Fusaroli, P., additional, Giacomoni, P.L., additional, Lenzi, M., additional, and Pedretti, G., additional
- Published
- 2016
- Full Text
- View/download PDF
23. Moderate alcohol use and health: A consensus paper
- Author
-
Poli, A, Marangoni, F, Avogaro, Angelo, Barba, G, Bellentani, S, Bucci, M, Cambieri, R, Catapano, Al, Costanzo, S, Cricelli, C, de Gaetano, G, Di Castelnuovo, A, Faggiano, P, Fattirolli, F, Fontana, L, Forlani, G, Frattini, S, Giacco, R, La Vecchia, C, Lazzaretto, L, Loffredo, L, Lucchin, L, Marelli, G, Marrocco, W, Minisola, S, Musicco, M, Novo, S, Nozzoli, C, Pelucchi, C, Perri, L, Pieralli, F, Rizzoni, D, Sterzi, R, Vettor, R, Violi, F, Visioli, F., Poli, A, Marangoni, F, Avogaro, A, Barba, G, Bellentani, S, Bucci, M, Cambieri, R, Catapano, AL, Costanzo, S, Cricelli, C, de Gaetano, G, Di Castelnuovo, A, Faggiano, P, Fattirolli, F, Fontana, L, Forlani, G, Frattini, S, Giacco, R, La Vecchia, C, Lazzaretto, L, Loffredo, L, Lucchin, L, Marelli, G, Marrocco, W, Minisola, S, Musicco, M, Novo, S, Nozzoli, C, Pelucchi, C, Perri, L, Pieralli, F, Rizzoni, D, Sterzi, R, Vettor, R, Violi, F, and Visioli, F
- Subjects
Alcohol, health - Abstract
AIMS: The aim of this consensus paper is to review the available evidence on the association between moderate alcohol use, health and disease and to provide a working document to the scientific and health professional communities. DATA SYNTHESIS: In healthy adults and in the elderly, spontaneous consumption of alcoholic beverages within 30 g ethanol/d for men and 15 g/d for women is to be considered acceptable and do not deserve intervention by the primary care physician or the health professional in charge. Patients with increased risk for specific diseases, for example, women with familiar history of breast cancer, or subjects with familiar history of early cardiovascular disease, or cardiovascular patients should discuss with their physician their drinking habits. No abstainer should be advised to drink for health reasons. Alcohol use must be discouraged in specific physiological or personal situations or in selected age classes (children and adolescents, pregnant and lactating women and recovering alcoholics). Moreover, the possible interactions between alcohol and acute or chronic drug use must be discussed with the primary care physician. CONCLUSIONS: The choice to consume alcohol should be based on individual considerations, taking into account the influence on health and diet, the risk of alcoholism and abuse, the effect on behaviour and other factors that may vary with age and lifestyle. Moderation in drinking and development of an associated lifestyle culture should be fostered.
- Published
- 2013
24. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee
- Author
-
Loria, P., Adinolfi, L. E., Bellentani, S., Bugianesi, E., Grieco, A., Fargion, S., Gasbarrini, A., Loguercio, C., Lonardo, A., Marchesini, G., Marra, F., Marcello Persico, Prati, D., Svegliati Baroni, G., N. A. F., Loria, P, Adinolfi, Luigi Elio, Bellentani, S, Bugianesi, E, Grieco, A, Fargion, S, Gasbarrini, A, Loguercio, Carmelina, Lonardo, A, Marchesini, G, Marra, F, Persico, M, Prati, D, Baroni, Gs, P. Loria, L.E. Adinolfi, S. Bellentani, E. Bugianesi, A. Grieco, S. Fargion, A. Gasbarrini, C. Loguercio, A. Lonardo, G. Marchesini Reggiani, F. Marra, M. Persico, D. Prati, G. Svegliati- Baroni, and The NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato (AISF)
- Subjects
Fatty Liver ,diagnosis/therapy, Humans, Italy, Societies ,Medical ,nonalcoholic fatty liver disease ,guidelines ,treatment ,diagnosis ,diagnosis/therapy ,Italy ,NAFLD ,management ,Settore MED/09 - MEDICINA INTERNA ,Humans ,Societies ,Societies, Medical - Abstract
We report the evidence-based Italian Association for the Study of Liver guidelines for the appropriate diagnosis and management of patients with nonalcoholic fatty liver disease in clinical practice and its related research agenda. The prevalence of nonalcoholic fatty liver disease varies according to age, gender and ethnicity. In the general population, the prevalence of nonalcoholic fatty liver disease is about 25% and the incidence is of two new cases/100 people/year. 2-3% of individuals in the general population will suffer from nonalcoholic steatohepatitis. Uncomplicated steatosis will usually follow a benign course. Individuals with nonalcoholic steatohepatitis, however, have a reduced life expectancy, mainly owing to vascular diseases and liver-related causes. Moreover, steatosis has deleterious effects on the natural history of HCV infection. Nonalcoholic fatty liver disease is usually diagnosed in asymptomatic patients prompted by the occasional discovery of increased liver enzymes and/or of ultrasonographic steatosis. Medical history, complete physical examination, etiologic screening of liver injury, liver biochemistry tests, serum lipids and insulin sensitivity tests should be performed in every patient. Occult alcohol abuse should be ruled out. Ultrasonography is the first-line imaging technique. Liver biopsy, the gold standard in diagnosis and prognosis of nonalcoholic fatty liver disease, is an invasive procedure and its results will not influence treatment in most cases but will provide prognostic information. Assessment of fibrosis by composite scores, specific laboratory parameters and transient elastography might reduce the number of nonalcoholic fatty liver disease patients requiring liver biopsy. Dieting and physical training reinforced by behavioural therapy are associated with improved nonalcoholic fatty liver disease. Diabetes and the metabolic syndrome should be ruled out at timed intervals in nonalcoholic fatty liver disease. Nonalcoholic steatohepatitis patients should undergo periodic evaluation of cardiovascular risk and of advancement of their liver disease; those with nonalcoholic steatohepatitis-cirrhosis should be evaluated for early diagnosis of hepatocellular carcinoma.
- Published
- 2010
25. A web-based program for implementing lifestyle changing towards healthy diet and habitual physical activity in NAFLD
- Author
-
Mazzotti, A., Bugianesi, Elisabetta, Bellentani, S., Barchetti, A., Vanni, Ester, Marzocchi, R., and Marchesini, G.
- Published
- 2014
26. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
- Author
-
Rosina, Floriano, Tosti, Maria Elena, Borghesio, Elisabetta, Masocco, Maria, Mele, Alfonso, Coppola, Carmine, Milella, Michele, Borgia, Guglielmo, Andreone, Pietro, Koch, Maurizio, Zignego, Anna Linda, Romano, Mario, Carrara, Maurizio, Almasio, Piero Luigi, Azzola, Emilio, Nardone, Gerardo, Benedetti, Antonio, Carosi, Giampiero, Mazzotta, Francesco, Sagnelli, Evangelista, Rizzetto, Mario, Mascolo, M. C., Cursaro, C., Scuteri, A., Crespi, C., Gianstefani, A., Ranieri, J., Monti, M., Corti, G., Blanc, P. L., Baragli, F., Bellentani, S., Gasbarrini, A., Pompili, M., Mecenate, F., Picardi, A., Vespasiani, U., Nosotti, Null, Null, A. Picardi, Ricci, G. L., Paffetti, A., Mastropietro, C., Moretti, A., Spagnolo, A. L., Puoti, C., Bellis, L., Regazzetti, A., Maffezzini, E., Pietrangelo, A., Abbati, G., Borghi, A., Sardini, C., Raimondo, G., Scribano, L., Martines, D., Svegliati Baroni, G., Faraci, G., Schi anchi, S., Fornaciari, G., Massari, M., Fabris, P., Bertin, T., Salvagnini, M., Madonia, S., Calì, A., Civitavecchia, G., Pirisi, M., Smirne, C., Andreoletti, M., Morisco, F., Caporaso, N., Gentile, I., Brancaccio, G., Gaeta, G. B., Liberti, A., Iannece, M. D., Rocco, A., Federico, A., Loguercio, C., Riegler, G., Esposito, P., Fargion, S., Fatta, E., Masutti, F., Bonaventura, M. E., Autolitano, A., Russello, M., Bellia, A., Toniutto, P., Bitetto, D., Pasulo, L., Lucà, M. G., Grattagliano, I., Palasciano, G., Romagno, D., Giannelli, G., Napoli, N., Plattella, M. S., Cassano, P., Gobbo, G., Monti, V., Raspanti, A., Cuccorese, Null, Colombo, A. E., Mandelli, G., Spinzi, G. C., Floridia, Null, Messina, V., Bonfante, S., Bellissima, P., Toti, M., Vecchiet, J., Falasca, K., Portelli, V., Stefano, G. De, Pietromatera, G., Viganò, P., Re, T., Andreoni, M., Null, G. Raineri, Grossi, P. A., Caputo, S., Cassola, G., Feasi, M., Biagio, A. Di, Nicolini, LAURA AMBRA, Giannini, EDOARDO GIOVANNI, Corbo, M., Foti, G., Kunkar, A., Caterini, L., Migliorini, D., Chiodera, A., Calleri, G., Spezia, C., Framarin, L., Null, M. Berrutti, Ciancio, A., Baiguera, C., Puoti, M., Vento, S., Contini, C., Boccia, S., Casiraghi, M. A., Simone, L., Tacconi, D., Caremani, M., Almi, P., Chimenti, M., Cosco, Null, Messeri, D., Esperti, F. C., Lomonaco, L., Pazzi, P., Fornari, F., Comparato, G., Casetti, T., Foschi, F. G., Samori, A., Ferretti, E., Marin, R., Campo, N., Testa, R., Rizzo, S., Rosina, F, Tosti, ME, Borghesio, E, Masocco, M, Mele, A, Coppola, C, Milella, M, Borgia, G, Andreone, P, Koch, M, Zignego, AL, Romano, M, Carrara, M, Almasio, PL, Azzola, E, Nardone, G, Benedetti, A, Carosi, G, Mazzotta, F, Sagnelli, E, Rizzetto, M, Rosina, F., Tosti, M. E., Borghesio, E., Masocco, M., Mele, A., Coppola, C., Milella, M., Borgia, Guglielmo, Andreone, P., Koch, M., Zignego, A. L., Romano, M., Carrara, M., Almasio, P. L., Azzola, E., Nardone, GERARDO ANTONIO PIO, Benedetti, A., Carosi, G., Mazzotta, F., Sagnelli, E., Rizzetto, M., Aifa, Aisf, Simit, Aigo, Sige, Gentile, Ivan, Morisco, Filomena, Et, Al, Floriano Rosina, Maria Elena Tosti, Elisabetta Borghesio, Maria Masocco, Alfonso Mele, Carmine Coppola, Michele Milella, Guglielmo Borgia, Pietro Andreone, Maurizio Koch, Anna Linda Zignego, Mario Romano, Maurizio Carrara, Piero Luigi Almasio, Emilio Azzola, Gerardo Nardone, Antonio Benedetti, Giampiero Carosi, Francesco Mazzotta, Evangelista Sagnelli, and Mario Rizzetto
- Subjects
Registrie ,Male ,Cirrhosis ,medicine.disease_cause ,Polyethylene Glycol ,Gastroenterology ,Polyethylene Glycols ,chemistry.chemical_compound ,Hepatitis Viruses ,Hepatitis Viruse ,Prospective Studies ,Viral ,Registries ,Chronic ,Prospective cohort study ,Drug Carrier ,Drug Carriers ,Settore MED/12 - Gastroenterologia ,Medicine (all) ,Recombinant Protein ,Middle Aged ,Hepatitis C ,Recombinant Proteins ,Treatment Outcome ,Italy ,Combination ,RNA, Viral ,Population study ,Drug Therapy, Combination ,Female ,Human ,medicine.medical_specialty ,Genotype ,Hepatitis C virus ,Alpha interferon ,Ribavirin ,Sustained virological response (SVR) ,Treatment ,Antiviral Agents ,Follow-Up Studie ,Hepatology ,Drug Therapy ,Internal medicine ,medicine ,Humans ,Antiviral Agent ,business.industry ,Interferon-alpha ,HCV therapy ,Hepatitis C, Chronic ,medicine.disease ,Clinical trial ,Prospective Studie ,chemistry ,Immunology ,RNA ,Follow-Up Studies ,business - Abstract
a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sustained virological response was achieved by 1036 patients (50.5%) during the retrospective phase: 325 were genotypes 1/4 (34.1%) and 684 were genotypes 2/3 (67.2%) and by 800 patients (38.6%) during the prospective phase: 300 were genotypes 1/4 (28.4%) and 473 were genotypes 2/3 (51.5%). During multivariate analysis genotypes 2/3 were significantly associated with higher sustained virological response rates; cirrhosis and -glutamil-transpeptidase >2 times the normal limit were associated with poorer response. Conclusions: The response to Peg-interferon/ribavirin therapy in “real world” clinical practice is distinctly lower than in registration trials. The difference in response rates was more pronounced among easy-totreat than among difficult-to-treat hepatitis C virus genotypes.
- Published
- 2014
27. Behavior Therapy for Nonalcoholic Fatty Liver Disease: Need for a Multidisciplinary Approach
- Author
-
Bellentani, S, Dalle Grave, R, Suppini, A, Marchesini, G, Bedogni, G, Bugianesi, E, Crocè, L, Gastaldelli, A, Marra, F, Svegliati Baroni, G, Tell, G, Tiribelli, C., PERSEGHIN, GIANLUCA, Bellentani, S, DALLE GAVE, R, Suppini, A, Croce', Saveria, Tiribelli, Claudio, Dalle Grave, R, Marchesini, G, Bedogni, G, Bugianesi, E, Crocè, L, Gastaldelli, A, Marra, F, Perseghin, G, Svegliati Baroni, G, Tell, G, Tiribelli, C, S. Bellentani, R. Dalle Grave, A. Suppini, and G. Marchesini Reggiani
- Subjects
Counseling ,medicine.medical_specialty ,obesity ,Referral ,Insulin resistance ,Weight loss ,Behavior Therapy ,Diabetes mellitus ,Nonalcoholic fatty liver disease ,medicine ,Humans ,Intensive care medicine ,MED/13 - ENDOCRINOLOGIA ,Life Style ,Patient Care Team ,diabetes ,Hepatology ,business.industry ,Fatty liver ,medicine.disease ,Obesity ,Surgery ,Diet ,Fatty Liver ,Treatment Outcome ,diabete ,Interdisciplinary Communication ,Metabolic syndrome ,medicine.symptom ,non alcoholic fatty liver disease (NAFLD) ,business - Abstract
Nonalcoholic fatty liver disease (NAFLD) is systematically associated with insulin resistance and the metabolic syndrome, where behavior therapy remains the primary treatment, simultaneously addressing all the clinical and biochemical defects. However, very few studies have tested the effectiveness of intensive behavior therapy in NAFLD, aimed at lifestyle modifications to produce stable weight loss by reduced calorie intake and increased physical activity. Searching the literature for studies testing weight loss and lifestyle modifications for the treatment of NAFLD, only 14 reports were traced where the entry assessment satisfied well-defined criteria. The final effectiveness was based on hard histological outcomes in 5 cases. All but 1 were pilot, uncontrolled studies or limited case series, and in general the details of treatment were scanty. In only 3 cases treatment was carried out along the guidelines of behavior treatment to reduce excess nutrition and increase exercise; in these cases, a remarkable effect on weight loss and an improvement in liver histology were reported. The principles of behavior therapy are presented in detail, to help physicians change their prescriptive attitude into a more empowerment-based approach. A brief section is also included on the practical aspects and public policies to be implemented at societal level to obtain the maximum effects in lifestyle changes. There is a need for multidisciplinary teams including dietitians, psychologists, and physical activity supervisors caring for patients with NAFLD. Alternatively, general practitioners and physicians working in gastrointestinal units should limit their intervention to engage patients with NAFLD before referral to specialized teams set up for the treatment of diabetes and obesity. Copyright © 2008 by the American Association for the Study of Liver Diseases
- Published
- 2008
28. Predictors of non-alcoholic fatty liver disease in obese children
- Author
-
SARTORIO A, DEL COL A, AGOSTI F, MAZZILLI G, BELLENTANI S, BEDOGNI G., TIRIBELLI, CLAUDIO, Sartorio, A, DEL COL, A, Agosti, F, Mazzilli, G, Bellentani, S, Tiribelli, Claudio, and Bedogni, G.
- Published
- 2006
29. Epidemiology of hepatitis C virus infection
- Author
-
Bellentani, S, Miglioli, L, Bedogni, G, Croce', Saveria, Tiribelli, Claudio, Bellentani, S, Miglioli, L, Bedogni, G, Croce', Saveria, and Tiribelli, Claudio
- Subjects
Epidemiology ,Hepatitis C virus infection ,Incidence ,Natural history ,Prevalence - Abstract
Although a lot of novel information and data on the epidemiology of hepatitis C virus (HCV) infection are available worldwide, the majority of these information are often fragmentary and sometimes contradictory. This review tries to highlight all the data available on the prevalence (i.e. the number of cases present in a known population), the risk factors, the natural history and the incidence (i.e. the number of new cases that occur every year) of HCV infection in the world, and particularly in Italy.
- Published
- 2005
30. A 'systems medicine' approach to the study of non-alcoholic fatty liver disease
- Author
-
Petta, S, Valenti, L, Bugianesi, E, Targher, G, GRIECO, ANTONIO, Bonino, F, Bellentani, S, Special Interest Group on Personalised Hepatology of the Italian Association for the Study of the Liver (AISF), Petta, S, Valenti, L, Bugianesi, E, Targher, G, GRIECO, ANTONIO, Bonino, F, Bellentani, S, and Special Interest Group on Personalised Hepatology of the Italian Association for the Study of the Liver (AISF)
- Published
- 2015
31. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
- Author
-
Lonardo, A., Bellentani, S., Argo, C. K., Ballestri, S., Byrne, C. D., Caldwell, S. H., Cortez-Pinto, H., Grieco, Antonio, Machado, M. V., Miele, Luca, Targher, G., Grieco A. (ORCID:0000-0002-0544-8993), Miele L. (ORCID:0000-0003-3464-0068), Lonardo, A., Bellentani, S., Argo, C. K., Ballestri, S., Byrne, C. D., Caldwell, S. H., Cortez-Pinto, H., Grieco, Antonio, Machado, M. V., Miele, Luca, Targher, G., Grieco A. (ORCID:0000-0002-0544-8993), and Miele L. (ORCID:0000-0003-3464-0068)
- Abstract
An improved understanding of non-alcoholic fatty liver disease epidemiology would lead to identification of individuals at high risk of developing chronic liver disease and extra-hepatic complications, thus contributing to more effective case finding of non-alcoholic fatty liver disease among selected groups.We aimed to illustrate the epidemiology of non-alcoholic fatty liver disease in high-risk groups, which were identified based on existing literature. To this end, PubMed was searched to retrieve original articles published until May 2015 using relevant and pertinent keywords "nonalcoholic fatty liver disease" and "diabetes", "obesity", "hyperlipidaemia", "familial heterozygous hypobetalipoproteinaemia", "hypertension", "metabolic syndrome", "ethnicity", "family history" or "genetic polymorphisms".We found that age, sex and ethnicity are major physiological modifiers of the risk of non-alcoholic fatty liver disease, along with belonging to "non-alcoholic fatty liver disease families" and carrying risk alleles for selected genetic polymorphisms. Metabolic syndrome, diabetes, obesity, mixed hyperlipidaemia and hypocholesterolaemia due to familial hypobetalipoproteinaemia are the major metabolic modifiers of non-alcoholic fatty liver disease risk. Compared with these metabolic conditions, however, arterial hypertension appears to carry a relatively more modest risk of non-alcoholic fatty liver disease.A better understanding of the epidemiology of non-alcoholic fatty liver disease may result in a more liberal policy of case finding among high-risk groups.
- Published
- 2015
32. THE NORTH-TO-SOUTH GRADIENT OF HEPATITIS C VIRUS INFECTION. (EDITORIAL)
- Author
-
Tiribelli, Claudio, Bellentani, S, Campello, C., Tiribelli, Claudio, Bellentani, S, and Campello, C.
- Published
- 2003
33. The north-to-south gradient of hepatitis C virus infection
- Author
-
TIRIBELLI, CLAUDIO, BELLENTANI S., CAMPELLO, CESARE, Tiribelli, Claudio, Bellentani, S., and Campello, Cesare
- Published
- 2003
34. BT-Paba test in the diagnosis of pancreatic exocrine insufficiency in cystic fibrosis: urinary and serum determinations compared
- Author
-
Bellentani, S., Grisendi, A., Rinaldi, M., Bertolani, P., Costa, G., agostini, M., Mastella, G., Balli, F., and Manenti, F.
- Published
- 1984
- Full Text
- View/download PDF
35. Study of the long-term effects of selective biliary obstruction (SBO)
- Author
-
Bellentani, S., Ferrari, A., Villa, E., and Manenti, F.
- Published
- 1981
- Full Text
- View/download PDF
36. HIGH PREVALENCE OF CELIAC DISEASE IN THE ITALIAN GENERAL POPULATION OF THE DIONYSOS STUDY
- Author
-
Volta, U, Bellentani, S, Bianchi, Fb, Brandi, G, DE FRANCESCHI, L, Miglioli, L, Granito, A, Tiribelli, Claudio, Volta, U, Bellentani, S, Bianchi, Fb, Brandi, G, DE FRANCESCHI, L, Miglioli, L, Granito, A, and Tiribelli, Claudio
- Published
- 2001
37. Prevalence And Risk Factors For Hepatic Steatosis In Northern Italy
- Author
-
BELLENTANI S, SACCOCCIO G, MASUTTI F, BRANDI G, SASSO F, CRISTIANINI G, CROCE', Saveria, Lory, TIRIBELLI, CLAUDIO, Bellentani, S, Saccoccio, G, Masutti, F, Croce', Saveria, Brandi, G, Sasso, F, Cristianini, G, and Tiribelli, Claudio
- Subjects
Adult ,Male ,Questionnaires ,Adolescent ,Aged ,Alanine Transaminase ,Alcoholism ,Biological Markers ,Child ,Cross-Sectional Studies ,Fatty Liver ,Female ,gamma-Glutamyltransferase ,Humans ,Italy ,Liver ,Middle Aged ,Obesity ,Prevalence ,Risk Factors ,Triglycerides ,Cross-Sectional Studie ,Questionnaire ,Risk Factor ,Biological Marker ,Human - Abstract
Background: Although hepatic steatosis is seen with increasing frequency in clinical practice, its prevalence and risk factors are unknown. Objective: To investigate the prevalence of and risk factors for hepatic steatosis, such as alcohol consumption and obesity. Design: Cross-sectional, observational study. Setting: Participants in the Dionysos Study. Patients: 257 participants assigned to one of four categories (67 controls, 66 obese persons, 69 heavy drinkers, and 55 obese heavy drinkers). Measurements: Ethanol intake, assessed by a validated questionnaire and expressed as daily (g/d) and lifetime (kg) consumption, and body mass, expressed as body mass index. Biochemical tests of liver and metabolic function and hepatic ultrasonography were done. Results: The prevalence of steatosis was increased in heavy drinkers (46.4% [95% CI, 34% to 59%]) and obese persons (75.8% [CI, 63% to 85%]) compared with controls (16.4% [CI, 8% to 25%]). Steatosis was found in 94.5% (CI, 85% to 99%) of obese heavy drinkers. Compared with controls, the risk for steatosis was higher by 2.8-fold (CI, 1.4-fold to 7.1 -fold) in heavy drinkers, 4.6-fold (CI, 2.5-fold to 11.0-fold) in obese persons, and 5.8-fold (Cl, 3.2-fold to 12.3-fold) in persons who were obese and drank heavily. In heavy drinkers, obesity increased the risk for steatosis by twofold (CI, 1.5-fold to 3.0-fold) (P< 0.001), but heavy drinking was associated with only a 1.3-fold (Cl, 1.02-fold to 1.6-fold) increase in risk in obese persons (P = 0.0053). Elevated alanine aminotransferase and triglyceride levels are the most reliable markers of steatosis. Conclusions: Steatosis is frequently encountered in healthy persons and is almost always present in obese persons who drink more than 60 g of alcohol per day. Steatosis is more strongly associated with obesity than with heavy drinking, suggesting a greater role of overweight than alcohol consumption in accumulation of fat in the liver.
- Published
- 2000
38. Risk Factors for alcoholic liver disease
- Author
-
Bellentani, S., Saccoccio, G., Masutti, F., MAURO GIACCA, Miglioli, L., Monzoni, A., Tiribelli, C., Bellentani, S, Saccoccio, G, Mansutti, F, Giacca, Mauro, Miglioli, L, Monzoni, A, and Tiribelli, Claudio
- Published
- 2000
39. Clinical course and risk factors of HCV-related liver disease in the general population: Report from the Dionysos Study
- Author
-
Bellentani, S, Pozzato, Gabriele, Saccoccio, G, Crovatto, M, Croce', Saveria, Mazzoran, L, Masutti, F, Cristianini, G, Tiribelli, Claudio, Bellentani, S, Pozzato, Gabriele, Saccoccio, G, Crovatto, M, Croce', Saveria, Mazzoran, L, Masutti, F, Cristianini, G, and Tiribelli, Claudio
- Subjects
Cirrhosis, Dionysos, Hepatitis C virus genotypes, Liver disease ,Hepatitis C virus genotypes ,Cirrhosis ,Dionysos ,Liver disease - Abstract
Background - The severity, clinical course, and risk of hepatitis C virus (HCV) related chronic liver disease are still rather poorly defined. Aims - To investigate the prevalence, risk factors, and severity of HCV related liver disease in the general population, and investigate whether infection with a specific genotype is associated with an increased risk of cirrhosis or hepatocellular carcinoma. Methods - HCV RNA determination by polymerase chain reaction (PCR) and HCV genotyping were performed in all anti-HCV positive subjects belonging to the Dionysos study (6917 subjects). Diagnosis of cirrhosis and hepatocellular carcinoma was established by liver biopsy in all cases. All the data were analysed by univariate and multivariate statistics in all the cohort. To investigate the natural history of HCV infection, anti-HCV positive subjects were followed up every six months for three years with liver function tests and ultrasonograms. Results - The overall prevalence of HCV RNA positivity was 2.3%. Positivity increased progressively with age, and was higher in women (ratio of men to women = 0.7). Genotypes 1b and 2a were the most frequent (42 and 24% of HCV RNA positive patients), with a prevalence of 1 and 0.6% respectively. Intravenous drug use, blood transfusions received before 1990, history of previous hepatitis among the cohabiting, and history of animal (mainly dogs) bites were significantly (p
- Published
- 1999
40. Drinking habits as cofactors of risk for alcoholic-induced liver damage
- Author
-
BELLENTANI S, SACCOCCIO G, COSTA G, TIRIBELLI, CLAUDIO, MANENTI F, SODDE M, SASSO F, POZZATO, GABRIELE, CRISTIANINI G, BRANDI G. AND THE DIONYSOS STUDY GROUP, CROCE', Saveria, Lory, Bellentani, S, Saccoccio, G, Costa, G, Tiribelli, Claudio, Manenti, F, Sodde, M, Croce', Saveria, Sasso, F, Pozzato, Gabriele, Cristianini, G, and BRANDI G., AND THE DIONYSOS STUDY GROUP
- Published
- 1999
41. P0340 : Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): A multicenter case-control study
- Author
-
Piscaglia, F., primary, Svegliati Baroni, G., additional, Barchetti, A., additional, Pecorelli, A., additional, Marinelli, S., additional, Tiribelli, C., additional, Bellentani, S., additional, Bolondi, L., additional, Zoli, M., additional, Trevisani, F., additional, Malagotti, D., additional, Bugianesi, E., additional, Vanni, E., additional, Mezzabotta, L., additional, Cabibbo, G., additional, Petta, S., additional, Fracanzani, A., additional, Fargion, S., additional, Marra, F., additional, Fani, B., additional, Sacco, R., additional, Morisco, F., additional, Caporaso, F., additional, and Guarino, M., additional
- Published
- 2015
- Full Text
- View/download PDF
42. Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): a multicenter case-control study
- Author
-
Piscaglia, F., primary, Baroni, G. Svegliati, additional, Barchetti, A., additional, Pecorelli, A., additional, Marinelli, S., additional, Tiribelli, C., additional, Bellentani, S., additional, Bolondi, L., additional, Zoli, M., additional, Malagotti, D., additional, Brandi, G., additional, Bugianesi, E., additional, Vanni, E., additional, Mezzabotta, L., additional, Cabibbo, G., additional, Petta, S., additional, Fracanzani, A., additional, Fargion, S., additional, Marra, F., additional, Fani, B., additional, Sacco, R., additional, Morisco, F., additional, Caporaso, N., additional, Guarino, M., additional, Colombo, M., additional, D’Ambrosio, R., additional, Crocè, L.S., additional, Patti, R., additional, Giannini, E., additional, Lonardo, A., additional, Baldelli, E., additional, Miele, L., additional, Grieco, A., additional, Farinati, F., additional, Pozzan, C., additional, Borzio, M., additional, Dionigi, E., additional, Soardo, G., additional, Roselli, P., additional, Ciccarese, F., additional, Virdone, F., additional, Affronti, A., additional, Foschi, F.G., additional, Borzio, F., additional, and Trevisani, F., additional
- Published
- 2015
- Full Text
- View/download PDF
43. High g-glutamyl-transferase fractions as new markers to identify non-alcoholic fatty liver disease in childhood obesity
- Author
-
Predieri, Barbara, Bruzzi, Patrizia, Lami, Francesca, Miglioli, L., Bellentani, S., Vellani, Giulia, Balli, F., Gastaldelli, A., and Iughetti, Lorenzo
- Subjects
Non-alcoholic fatty liver disease ,Childhood ,Obesity - Published
- 2009
44. A new device for measuring resting energy expenditure in severely obese children and adolescents with and without non-alcoholic fatty liver disease
- Author
-
Predieri, Barbara, Lami, Francesca, Bruzzi, Patrizia, Vellani, Giulia, Dugoni, M., Miglioli, L., Bellentani, S., Balli, F., and Iughetti, Lorenzo
- Subjects
obesity ,non-alcoholic fatty liver disease ,Energy expenditure - Published
- 2008
45. Prevalence of chronic liver diseases in the general population of Northern Italy: The Dionysos study
- Author
-
BELLENTANI S, TIRIBELLI, CLAUDIO, G. SACCOCCIO, M. SODDE, N. FRATTI, C. DE MARTIN, G. CRISTIANINI, CROCE', Saveria, Lory, Bellentani, S, Tiribelli, Claudio, G., Saccoccio, M., Sodde, N., Fratti, C., DE MARTIN, G., Cristianini, and Croce', Saveria
- Published
- 1994
46. PREVALENCE OF CHRONIC LIVER-DISEASE IN THE GENERAL-POPULATION OF NORTHERN ITALY - THE DIONYSOS STUDY
- Author
-
Bellentani S., TIRIBELLI, CLAUDIO, Saccoccio G., Sodde M., Fratti N., Demartin C., Cristianini G., Armocida C., Barbani A., Baroni D., Brandi G., CROCE', Saveria, Lory, Ferretti I., Figlioli G. F., Manenti A. L., Manenti F., Marchegiano P., Messori B., Poppi C., Sassatelli R., PASSAMONTI, SABINA, Bellentani, S., Tiribelli, Claudio, Saccoccio, G., Sodde, M., Fratti, N., Demartin, C., Cristianini, G., Armocida, C., Barbani, A., Baroni, D., Brandi, G., Croce', Saveria, Ferretti, I., Figlioli, G. F., Manenti, A. L., Manenti, F., Marchegiano, P., Messori, B., Passamonti, Sabina, Poppi, C., and Sassatelli, R.
- Subjects
Liver Cirrhosis ,Male ,Cirrhosis ,Prevalence ,population ,Chronic liver disease ,Body Mass Index ,Cohort Studies ,Prospective Studies ,Child ,medicine.diagnostic_test ,alcohol ,Liver Diseases ,Liver Neoplasms ,Age Factors ,Hepatitis C ,hepatocellular carcinoma ,Middle Aged ,Hepatitis B ,hepatitis viral infections ,hepatitis viral infection ,chronic liver disease ,Italy ,Population Surveillance ,Hepatocellular carcinoma ,Liver biopsy ,Female ,Adult ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Adolescent ,Sex Factors ,Internal medicine ,medicine ,Humans ,Liver Diseases, Alcoholic ,Aged ,Chi-Square Distribution ,Hepatology ,business.industry ,medicine.disease ,Surgery ,Chronic Disease ,business ,Liver function tests ,Follow-Up Studies - Abstract
Data on the prevalence of chronic liver disease, derived from selected series of hospitalized patients or from mortality registers, underestimate the prevalence of chronic liver disease. The Dionysos Study is a cohort study that investigated for the first time the prevalence of chronic liver disease in a general population. All the citizens of two towns in northern Italy, Campogalliano and Cormons, aged 12 to 65 yr were contacted by letter. From March 1991 through March 1993, 6,917 of a total of 10,150 citizens were enrolled (compliance, 69%). The standardized protocol for each enrollee included (a) a color-illustrated food questionnaire on dietary habits and alcohol intake; (b) a detailed medical history, including questions on risk factors for chronic liver disease; (c) a physical examination; and (d) blood tests for AST, ALT, γ-glutamyl-transpeptidase, mean cell volume, platelet count and hepatitis B virus and hepatitis C virus markers. Signs suggestive of chronic liver disease were seen in 21.3% of the subjects, and who then underwent further liver function tests, upper abdominal ultrasonography and, when necessary, liver biopsy. Persistent signs of chronic liver disease were present in 17.5% of the subjects, including 1.1% with cirrhosis and 0.07% with hepatocellular carcinoma. The prevalence rates of hepatitis B virus and hepatitis C virus positivity (second-generation enzyme-linked immunosorbent assay) were 1.3% and 3.2%, respectively. Alcohol abuse was the etiological agent in 23%. Other factors which predisposed subjects to chronic liver disease were age older than 35 yr, male sex, body mass index higher than 27, history of blood transfusion, drug addiction and presence of chronic liver disease in the subject's family. Cirrhosis was due to hepatitis B virus or hepatitis C virus in 37%, and alcohol was the cause in 26%. In those subjects with alcohol abuse, viral infection, especially hepatitis C virus, played an important role in the deterioration of chronic liver disease and its progression to hepatocellular carcinoma. We conclude that the Dionysos study, the first study of the prevalence of chronic liver disease in a general population of northern Italy, found a much higher prevalence of chronic liver disease than reported previously in selected populations from Western countries. Hepatitis viral infections and alcoholism were the most important causative agents.
- Published
- 1994
47. P808 A WEB-BASED PROGRAM FOR IMPLEMENTING LIFESTYLE CHANGES TOWARDS HEALTHY DIET AND HABITUAL PHYSICAL ACTIVITY IN NAFLD
- Author
-
Mazzotti, A., primary, Bugianesi, E., additional, Bellentani, S., additional, Barchetti, A., additional, Vanni, E., additional, Marzocchi, R., additional, and Marchesini, G., additional
- Published
- 2014
- Full Text
- View/download PDF
48. OC.04.2 CORRELATION BETWEEN DIET AND NON-ALCOHOLIC FATTY LIVER DISEASE: INVESTIGATION OF A COHORT OF ITALIAN PATIENTS
- Author
-
Abenavoli, L., primary, Pellegrini, M., additional, Busacchi, M., additional, Marchesini, G., additional, Bugianesi, E., additional, Barchetti, A., additional, and Bellentani, S., additional
- Published
- 2014
- Full Text
- View/download PDF
49. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee
- Author
-
Loria, P, Adinolfi, Le, Bellentani, S, Bugianesi, E, Grieco, Alessandro, Fargion, S, Gasbarrini, Antonio, Loguercio, C, Lonardo, A, Marchesini, G, Marra, F, Persico, M, Prati, D, Baroni, Gs, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Loria, P, Adinolfi, Le, Bellentani, S, Bugianesi, E, Grieco, Alessandro, Fargion, S, Gasbarrini, Antonio, Loguercio, C, Lonardo, A, Marchesini, G, Marra, F, Persico, M, Prati, D, Baroni, Gs, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)
- Abstract
We report the evidence-based Italian Association for the Study of Liver guidelines for the appropriate diagnosis and management of patients with nonalcoholic fatty liver disease in clinical practice and its related research agenda. The prevalence of nonalcoholic fatty liver disease varies according to age, gender and ethnicity. In the general population, the prevalence of nonalcoholic fatty liver disease is about 25% and the incidence is of two new cases/100 people/year. 2-3% of individuals in the general population will suffer from nonalcoholic steatohepatitis. Uncomplicated steatosis will usually follow a benign course. Individuals with nonalcoholic steatohepatitis, however, have a reduced life expectancy, mainly owing to vascular diseases and liver-related causes. Moreover, steatosis has deleterious effects on the natural history of HCV infection. Nonalcoholic fatty liver disease is usually diagnosed in asymptomatic patients prompted by the occasional discovery of increased liver enzymes and/or of ultrasonographic steatosis. Medical history, complete physical examination, etiologic screening of liver injury, liver biochemistry tests, serum lipids and insulin sensitivity tests should be performed in every patient. Occult alcohol abuse should be ruled out. Ultrasonography is the first-line imaging technique. Liver biopsy, the gold standard in diagnosis and prognosis of nonalcoholic fatty liver disease, is an invasive procedure and its results will not influence treatment in most cases but will provide prognostic information. Assessment of fibrosis by composite scores, specific laboratory parameters and transient elastography might reduce the number of nonalcoholic fatty liver disease patients requiring liver biopsy. Dieting and physical training reinforced by behavioural therapy are associated with improved nonalcoholic fatty liver disease. Diabetes and the metabolic syndrome should be ruled out at timed intervals in nonalcoholic fatty liver disease. Nonalcoholic s
- Published
- 2010
50. Clinical update on non-alcoholic fatty liver disease and steatohepatitis
- Author
-
Bugianesi, E, Bellentani, S, Bedogni, G, Tiribelli, C, Svegliati Baroni, G, Crocè, L, Gastaldelli, A, Marchesini, G, Marra, F, Perseghin, G, Tell, G, Tell, G., PERSEGHIN, GIANLUCA, Bugianesi, E, Bellentani, S, Bedogni, G, Tiribelli, C, Svegliati Baroni, G, Crocè, L, Gastaldelli, A, Marchesini, G, Marra, F, Perseghin, G, Tell, G, Tell, G., and PERSEGHIN, GIANLUCA
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.